Immune checkpoint inhibitors have transformed the management of patients with advanced kidney cancer. However, these therapies only work for a subset of patients with advanced disease and can be associated with substantial side effects. As a result, researchers are focused on new therapeutic combinations to boost the effectiveness of current immune therapies in renal cancer, including in patient populations with early-stage disease that is likely to recur.
Ureteroscopy is one of the most common procedures performed by urologists. Yet little is known about what optimizes the procedure’s success, especially in terms of how the urologist holds the ureteroscope and which hand and arm movements are most effective.
Communication breakdowns and poor teamwork are major contributors to preventable patient harm during surgery. To combat these and other threats to patient safety, surgical teams at Brigham and Women’s Hospital have long been provided with training that simulates crises in the operating room (OR). The proactive nature of these simulations is something that the Brigham’s Division of Urology finds invaluable.
Physicians have a good sense of the symptoms and causes of overactive bladder, and clear guidelines exist for diagnosis. Thanks to advertising for pharmaceuticals and other products, even many members of the general public are aware of this condition and know that treatments are available.
Although surgery and radiation provide good disease control for localized prostate cancer, developing long-lasting approaches for treating metastatic disease has been challenging because resistance to androgen deprivation therapy (ADT) frequently develops.
Members of the Brigham and Women’s Hospital community celebrated in October upon learning that William G. Kaelin Jr., MD, a senior physician-scientist at the Brigham, had won the 2019 Nobel Prize in Physiology or Medicine.
Complications and high readmission rates are a persistent challenge following radical cystectomy for the treatment of bladder cancer. The complex, intrabdominal operation, which includes replacement of the bladder or creation of a stoma, and often includes removal of reproductive organs as well, is associated with a high rate of morbidity. Patients undergoing the procedure often have additional risk factors for venous thromboembolism (VTE), such as pre-operative chemotherapy, older age and a history of smoking, and VTE is estimated to occur in 5.5 to 8.5 percent of patients and cost more than $10,000 per event. In a comprehensive effort to reduce risk of VTE, reduce length of stay and improve other measures of quality of care, Brigham and Women’s Hospital urologists have implemented a perioperative VTE prophylaxis program and analyzed its results, reporting key quality of care improvements. In addition, in collaboration with nurses, anesthesiologists, pharmacists and other members of patients’ care teams, clinicians in the Division of Urology are exploring innovative initiatives to continue to make strides in improving patient care. Read More
Urologists and oncologists at Dana-Farber/Brigham and Women’s Cancer Center have laid the groundwork for what would be the first Phase III international, randomized trial of a new treatment for patients with high-risk prostate cancer in more than a decade. The treatment involves using novel, potent neoadjuvant hormone therapy for six months prior to prostatectomy surgery, an approach that has been shown to improve both tumor pathology and long-term remission. Read More
The modification of the androgen axis plays a central role in men’s health, from maintaining vitality to controlling prostate cancer. Trying to balance the side effects and benefits of altering this axis is a fertile area of research.